TVTX logo

Travere Therapeutics (TVTX) Cash From Operations

Annual CFO

-$237.47 M
+$42.55 M+15.19%

December 31, 2024


Summary


Performance

TVTX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTVTXcash flowmetrics:

Quarterly CFO

-$35.72 M
+$6.79 M+15.97%

December 1, 2024


Summary


Performance

TVTX Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTVTXcash flowmetrics:

TTM CFO

-$237.47 M
+$34.75 M+12.77%

December 1, 2024


Summary


Performance

TVTX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTVTXcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

TVTX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+15.2%+49.3%+15.2%
3 y3 years-1505.4%+49.3%+15.2%
5 y5 years-307.9%+49.3%+15.2%

TVTX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-1505.4%+15.2%-32.9%+70.0%-1505.4%+25.3%
5 y5-year-1505.4%+15.2%-211.4%+70.0%<-9999.0%+25.3%
alltimeall time-3307.8%+15.2%-211.4%+70.0%-3307.8%+25.3%

Travere Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-$237.47 M(-15.2%)
-
-
Dec 2024
-
-$35.72 M(-16.0%)
-$237.47 M(-12.8%)
Sep 2024
-
-$42.51 M(+5.6%)
-$272.23 M(-5.8%)
Jun 2024
-
-$40.24 M(-66.2%)
-$288.86 M(-9.1%)
Mar 2024
-
-$119.00 M(+68.9%)
-$317.91 M(+13.5%)
Dec 2023
-$280.02 M(+50.3%)
-$70.47 M(+19.2%)
-$280.02 M(+6.0%)
Sep 2023
-
-$59.13 M(-14.7%)
-$264.19 M(+8.0%)
Jun 2023
-
-$69.30 M(-14.6%)
-$244.58 M(+15.3%)
Mar 2023
-
-$81.12 M(+48.5%)
-$212.09 M(+13.8%)
Dec 2022
-$186.29 M(+1159.4%)
-$54.64 M(+38.2%)
-$186.29 M(+17.5%)
Sep 2022
-
-$39.52 M(+7.4%)
-$158.53 M(+82.3%)
Jun 2022
-
-$36.81 M(-33.5%)
-$86.94 M(+99.2%)
Mar 2022
-
-$55.32 M(+105.8%)
-$43.64 M(+195.0%)
Dec 2021
-$14.79 M(-65.4%)
-$26.88 M(-183.8%)
-$14.79 M(+728.7%)
Sep 2021
-
$32.06 M(+393.6%)
-$1.78 M(-93.4%)
Jun 2021
-
$6.50 M(-124.5%)
-$27.11 M(-32.3%)
Mar 2021
-
-$26.47 M(+90.9%)
-$40.06 M(-6.3%)
Dec 2020
-$42.74 M(-26.6%)
-$13.87 M(-305.9%)
-$42.74 M(+28.1%)
Sep 2020
-
$6.74 M(-204.4%)
-$33.37 M(-38.5%)
Jun 2020
-
-$6.45 M(-77.9%)
-$54.22 M(-18.9%)
Mar 2020
-
-$29.16 M(+549.0%)
-$66.88 M(+14.9%)
Dec 2019
-$58.21 M(+133.2%)
-$4.49 M(-68.2%)
-$58.21 M(+1.6%)
Sep 2019
-
-$14.12 M(-26.1%)
-$57.29 M(+21.7%)
Jun 2019
-
-$19.11 M(-6.7%)
-$47.06 M(+53.2%)
Mar 2019
-
-$20.49 M(+474.8%)
-$30.72 M(+23.1%)
Dec 2018
-$24.96 M(-437.1%)
-$3.56 M(-8.6%)
-$24.96 M(+12.2%)
Sep 2018
-
-$3.90 M(+41.3%)
-$22.25 M(+83.1%)
Jun 2018
-
-$2.76 M(-81.3%)
-$12.15 M(+209.6%)
Mar 2018
-
-$14.73 M(+1625.3%)
-$3.92 M(-153.0%)
Dec 2017
$7.40 M
-$854.00 K(-113.8%)
$7.40 M(-3236.9%)
Sep 2017
-
$6.20 M(+13.4%)
-$236.00 K(-86.9%)
DateAnnualQuarterlyTTM
Jun 2017
-
$5.47 M(-260.4%)
-$1.80 M(-45.0%)
Mar 2017
-
-$3.41 M(-59.9%)
-$3.28 M(-4.6%)
Dec 2016
-$3.44 M(+147.7%)
-$8.49 M(-283.5%)
-$3.44 M(-329.4%)
Sep 2016
-
$4.63 M(+16.0%)
$1.50 M(-162.8%)
Jun 2016
-
$3.99 M(-211.9%)
-$2.39 M(-245.9%)
Mar 2016
-
-$3.57 M(+0.4%)
$1.64 M(-217.9%)
Dec 2015
-$1.39 M(-97.0%)
-$3.55 M(-580.6%)
-$1.39 M(-80.0%)
Sep 2015
-
$739.00 K(-90.8%)
-$6.93 M(-70.1%)
Jun 2015
-
$8.02 M(-221.6%)
-$23.17 M(-45.7%)
Mar 2015
-
-$6.59 M(-27.5%)
-$42.64 M(-7.0%)
Dec 2014
-$45.85 M(+160.7%)
-$9.10 M(-41.3%)
-$45.85 M(+2.1%)
Sep 2014
-
-$15.50 M(+35.4%)
-$44.90 M(+40.1%)
Jun 2014
-
-$11.45 M(+16.8%)
-$32.06 M(+40.5%)
Mar 2014
-
-$9.81 M(+20.4%)
-$22.82 M(+29.7%)
Dec 2013
-$17.59 M(+542.7%)
-$8.15 M(+206.8%)
-$17.59 M(+86.3%)
Sep 2013
-
-$2.66 M(+20.2%)
-$9.44 M(+39.1%)
Jun 2013
-
-$2.21 M(-51.8%)
-$6.79 M(+48.2%)
Mar 2013
-
-$4.58 M(<-9900.0%)
-$4.58 M(<-9900.0%)
Dec 2012
-$2.74 M(<-9900.0%)
-
-
Nov 2012
-
$0.00(0.0%)
$0.00(0.0%)
Aug 2012
-
$0.00(0.0%)
$0.00(0.0%)
May 2012
-
$0.00(0.0%)
$0.00(0.0%)
Feb 2012
-
$0.00(0.0%)
$0.00(-100.0%)
Feb 2012
$0.00(-100.0%)
-
-
Nov 2011
-
$0.00(0.0%)
-$600.00(-14.3%)
Aug 2011
-
$0.00(0.0%)
-$700.00(0.0%)
May 2011
-
$0.00(-100.0%)
-$700.00(0.0%)
Feb 2011
-$700.00
-$600.00(+500.0%)
-$700.00(+600.0%)
Nov 2010
-
-$100.00(<-9900.0%)
-$100.00(<-9900.0%)
Aug 2010
-
$0.00(0.0%)
$0.00(0.0%)
May 2010
-
$0.00
$0.00

FAQ

  • What is Travere Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Travere Therapeutics?
  • What is Travere Therapeutics annual CFO year-on-year change?
  • What is Travere Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Travere Therapeutics?
  • What is Travere Therapeutics quarterly CFO year-on-year change?
  • What is Travere Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Travere Therapeutics?
  • What is Travere Therapeutics TTM CFO year-on-year change?

What is Travere Therapeutics annual cash flow from operations?

The current annual CFO of TVTX is -$237.47 M

What is the all time high annual CFO for Travere Therapeutics?

Travere Therapeutics all-time high annual cash flow from operations is $7.40 M

What is Travere Therapeutics annual CFO year-on-year change?

Over the past year, TVTX annual cash flow from operations has changed by +$42.55 M (+15.19%)

What is Travere Therapeutics quarterly cash flow from operations?

The current quarterly CFO of TVTX is -$35.72 M

What is the all time high quarterly CFO for Travere Therapeutics?

Travere Therapeutics all-time high quarterly cash flow from operations is $32.06 M

What is Travere Therapeutics quarterly CFO year-on-year change?

Over the past year, TVTX quarterly cash flow from operations has changed by +$34.75 M (+49.31%)

What is Travere Therapeutics TTM cash flow from operations?

The current TTM CFO of TVTX is -$237.47 M

What is the all time high TTM CFO for Travere Therapeutics?

Travere Therapeutics all-time high TTM cash flow from operations is $7.40 M

What is Travere Therapeutics TTM CFO year-on-year change?

Over the past year, TVTX TTM cash flow from operations has changed by +$42.55 M (+15.19%)